MEPSGEN Launches NanoCalibur® Mini for Small-Volume Nanoparticle Formulation

• Automated system enables rapid, reproducible formulation screening with minimal sample consumption
• Completes the NanoCalibur® Series (Mini, Lab, Pro, GMP), supporting a seamless scale-up path from early research to GMP manufacturing

BOSTON, Oct. 26, 2026 /PRNewswire/ -- MEPSGEN US, Inc., a global innovator in drug delivery system platforms, today announced the launch of NanoCalibur® Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug discovery and development.

Nanoparticles are delivery vehicles that carry therapeutic payloads to target sites in the body, and they are central to next-generation modalities such as mRNA and gene therapies. Early-stage research requires repeated testing of many raw materials and process conditions, so the ability to generate fast, consistent results from limited material is essential.

NanoCalibur® Mini formulates lipid nanoparticles (LNPs) and polymeric nanoparticles at volumes of 0.1–3 mL. Built on MEPSGEN's proprietary microfluidic technology, it delivers precise, stable microfluidic flow control for rapid and highly reproducible formulation. Researchers can choose between two single-use microfluidic cartridges, 0.1–0.4 mL and 0.4–3 mL, to match their application, from early formulation screening through a range of preclinical studies. By enabling many formulation conditions to be tested quickly with minimal material, Mini helps accelerate development timelines while reducing reagent consumption and experimental costs.

One production architecture, from discovery to GMP

With the addition of Mini, the NanoCalibur® Series now spans four systems (Mini, Lab, Pro, and GMP), allowing customers to select the right platform for their development stage and production scale.

The defining feature of the series is a consistent formulation environment at every scale. NanoCalibur® Mini to Lab and to GMP uses the same microfluidic mixing pattern, with the same structure and dimensions. Rather than redesigning the mixer or changing the formulation conditions as production grows, NanoCalibur® increases throughput by parallelizing identical mixing units. This design is intended to reduce the need for process re-optimization during scale-up and technology transfer, while preserving nanoparticle quality and batch-to-batch reproducibility.

Protecting payload integrity at scale

In large-scale nanoparticle manufacturing, the high flow rates required for throughput can generate shear forces that damage sensitive payloads such as mRNA and reduce the potency. The NanoCalibur® Series is engineered to maintain stable shear conditions as production scales, helping preserve payload integrity and deliver consistent nanoparticle quality. More importantly, preserving payload potency will have the high potential to reduce the dose required for therapeutic effect, possibly addressing the high-dosage toxicity such as LNPs.

Launch promotion

To mark the launch of NanoCalibur® Mini, MEPSGEN will run a series of promotional offers through the end of the year for research institutions and pharmaceutical and biotechnology companies evaluating the system. Details will be announced on the MEPSGEN website and the company's official LinkedIn page.

"With NanoCalibur® Mini, we have extended our product lineup so that we can support customers more precisely at every stage, from early research through GMP manufacturing," said YongTae Kim, CEO of MEPSGEN. "We will continue to broaden the applications and customer base of the NanoCalibur® Series and strengthen our position in the global nanomedicine manufacturing market."

About MEPSGEN

MEPSGEN is a biotech company headquartered in Seoul, South Korea, with office in Cambridge, MA. The company was co-founded in 2019 by current CEO YongTae (Tony) Kim and Professor Robert Langer from MIT, a world-renowned expert in drug delivery and biomaterials who has pioneered numerous breakthroughs in controlled-release systems.

The company specializes in microphysiological system (MPS) and drug delivery system platforms based on its proprietary microfluidics technology. Its NanoCalibur® Series offers scalable nanoparticle formulation systems that support drug discovery, preclinical research, and GMP manufacturing, while its MPS platforms, including the MEPS-X Series and ProMEPS®, recreate the physiological function of human organs for New Approach Methodologies (NAMs). Together, they help pharmaceutical and biotech companies, universities, hospitals, and research institutions improve the efficiency and success rate of drug development.

For more information, please visit www.mepsgen.com or reach out to [email protected]

SOURCE MEPSGEN US, Inc.